Literature DB >> 9135872

The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1.

K Yamaguchi1, B Papp, D Zhang, A N Ali, S Agrawal, R A Byrn.   

Abstract

GEM 91 (gene expression modulator) is a 25-mer oligonucleotide phosphorothioate complementary to the gag initiation site of HIV-1. GEM 91 has been studied in various in vitro cell culture models to examine inhibitory effects on different stages of HIV-1 replication. Experiments were focused on the binding of virions to the cell surface, inhibition of virus entry, reverse transcription (HIV DNA production), inhibition of steady state viral mRNA levels, inhibition of virus production from chronically infected cells, and inhibition of HIV genome packaging within virions. Experiments were also performed in vitro in an attempt to generate strains of HIV with reduced sensitivity to GEM 91. We observed sequence-dependent inhibition of virus entry/reverse transcription and a reduction in steady state viral RNA levels. We also observed sequence-independent inhibition of virion binding to cells and inhibition of virus production by chronically infected cells. Using in vitro methods that were successful in generating HIV strains with reduced sensitivity to AZT, we were unable to generate strains with reduced sensitivity to GEM 91.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9135872     DOI: 10.1089/aid.1997.13.545

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

Authors:  S Sei; Q E Yang; D O'Neill; K Yoshimura; K Nagashima; H Mitsuya
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Lipid-based delivery of combinations of antisense oligodeoxynucleotides for the in vitro inhibition of HIV-1 replication.

Authors:  C Lavigne; J Yelle; G Sauvé; A G Thierry
Journal:  AAPS PharmSci       Date:  2001

3.  Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.

Authors:  Andrew Vaillant; Jean-Marc Juteau; Hong Lu; Shuwen Liu; Carol Lackman-Smith; Roger Ptak; Shibo Jiang
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides.

Authors:  G Lambert; E Fattal; H Pinto-Alphandary; A Gulik; P Couvreur
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

5.  Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles.

Authors:  M Berton; P Turelli; D Trono; C A Stein; E Allémann; R Gurny
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

6.  Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers.

Authors:  Andrew M Lee; Jillian M Rojek; Anette Gundersen; Ute Ströher; Jean-Marc Juteau; Andrew Vaillant; Stefan Kunz
Journal:  Virology       Date:  2007-11-26       Impact factor: 3.616

7.  Real time detection of DNA.RNA hybridization in living cells.

Authors:  D L Sokol; X Zhang; P Lu; A M Gewirtz
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

8.  Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.

Authors:  Moizza Mansoor; Alirio J Melendez
Journal:  Gene Regul Syst Bio       Date:  2008-09-22

9.  Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites.

Authors:  Martin R Jakobsen; Joost Haasnoot; Jesper Wengel; Ben Berkhout; Jørgen Kjems
Journal:  Retrovirology       Date:  2007-04-26       Impact factor: 4.602

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.